RBC Capital Reinstates Outperform on Bio-Techne, Announces $62 Price Target

Benzinga Newsdesk www.benzinga.com Positive 65.5%

Neg 0% Neu 0% Pos 65.5%

RBC Capital analyst Dan Leonard reinstates Bio-Techne (NASDAQ:TECH) with a Outperform and announces $62 price target.

Comments

No comments yet. Be the first!